PMID- 30706229
OWN - NLM
STAT- MEDLINE
DCOM- 20190708
LR  - 20200225
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Print)
IS  - 1068-9265 (Linking)
VI  - 26
IP  - 4
DP  - 2019 Apr
TI  - High Mean Corpuscular Volume Predicts Poor Outcome for Patients With 
      Gastroesophageal Adenocarcinoma.
PG  - 976-985
LID - 10.1245/s10434-019-07186-1 [doi]
AB  - BACKGROUND: Elevated mean corpuscular volume (MCV) is associated with a 
      diminished prognosis for various tumor entities. This study aimed to evaluate the 
      association between preoperative serum MCV levels and both overall (OS) and 
      disease-free survival (DFS) for patients with resectable adenocarcinomas of the 
      esophagogastric junction (AEG). METHODS: This study included consecutive patients 
      undergoing surgical resection between 1992 and 2016. Measured preoperative MCV 
      levels were stratified into quintiles and correlated with patients' survival and 
      clinicopathologic characteristics. RESULTS: The study analyzed 314 patients with 
      a median OS of 36.8 months and a median DFS of 20.6 months. The multivariate 
      analysis showed that preoperatively elevated MCV is a significant prognostic 
      factor for OS (hazard ratio [HR], 1.05; 95% confidence interval [CI], 1.03-1.08; 
      P < 0.001) and DFS (HR, 1.05; 95% CI, 1.03-1.08; P < 0.001). In the subgroup 
      analysis of neoadjuvantly treated and untreated patients, MCV remained an 
      independent prognostic factor for OS (HR, 1.08; 95% CI, 1.04-1.12; P < 0.001) and 
      DFS (HR, 1.07; 95% CI, 1.03-1.12; P < 0.001) in both groups. In the univariate 
      analysis, tumor stage and differentiation, adjuvant chemotherapy, MCV, mean 
      corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration 
      (MCHC) were significantly correlated with diminished OS and DFS. CONCLUSION: 
      Preoperatively elevated MCV is an independent prognostic factor for patients with 
      adenocarcinomas of the esophagus and the gastroesophageal junction.
FAU - Jomrich, Gerd
AU  - Jomrich G
AD  - Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor 
      Unit, Comprehensive Cancer Center (CCC), Vienna, Austria.
FAU - Hollenstein, Marlene
AU  - Hollenstein M
AD  - Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor 
      Unit, Comprehensive Cancer Center (CCC), Vienna, Austria.
FAU - John, Max
AU  - John M
AD  - Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor 
      Unit, Comprehensive Cancer Center (CCC), Vienna, Austria.
FAU - Ristl, Robin
AU  - Ristl R
AD  - Section for Medical Statistics (IMS), Center of Medical Statistics, Informatics 
      and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
FAU - Paireder, Matthias
AU  - Paireder M
AD  - Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor 
      Unit, Comprehensive Cancer Center (CCC), Vienna, Austria.
FAU - Kristo, Ivan
AU  - Kristo I
AD  - Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor 
      Unit, Comprehensive Cancer Center (CCC), Vienna, Austria.
FAU - Asari, Reza
AU  - Asari R
AD  - Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor 
      Unit, Comprehensive Cancer Center (CCC), Vienna, Austria.
FAU - Schoppmann, Sebastian F
AU  - Schoppmann SF
AD  - Department of Surgery, Medical University of Vienna, and Gastroesophageal Tumor 
      Unit, Comprehensive Cancer Center (CCC), Vienna, Austria. 
      sebastian.schoppmann@meduniwien.ac.at.
LA  - eng
PT  - Journal Article
DEP - 20190131
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
SB  - IM
MH  - Adenocarcinoma/blood/*mortality/pathology/therapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Combined Modality Therapy
MH  - *Erythrocyte Indices
MH  - Esophageal Neoplasms/blood/*mortality/pathology/therapy
MH  - Esophagogastric Junction/*pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoadjuvant Therapy/*mortality
MH  - Prognosis
MH  - Prospective Studies
MH  - Stomach Neoplasms/blood/*mortality/pathology/therapy
MH  - Survival Rate
PMC - PMC6399169
COIS- There are no conflicts of interest.
EDAT- 2019/02/02 06:00
MHDA- 2019/07/10 06:00
PMCR- 2019/01/31
CRDT- 2019/02/02 06:00
PHST- 2018/07/21 00:00 [received]
PHST- 2019/02/02 06:00 [pubmed]
PHST- 2019/07/10 06:00 [medline]
PHST- 2019/02/02 06:00 [entrez]
PHST- 2019/01/31 00:00 [pmc-release]
AID - 10.1245/s10434-019-07186-1 [pii]
AID - 7186 [pii]
AID - 10.1245/s10434-019-07186-1 [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2019 Apr;26(4):976-985. doi: 10.1245/s10434-019-07186-1. Epub 
      2019 Jan 31.